|
1
|
Zhang EL, Liang BY, Chen XP and Huang ZY:
Severity of liver cirrhosis: A key role in the selection of
surgical modality for Child-Pugh A hepatocellular carcinoma. World
J Surg Oncol. 13:1482015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kew MC: Epidemiology of chronic hepatitis
B virus infection, hepatocellular carcinoma, and hepatitis B
virus-induced hepatocellular carcinoma. Pathol Biol (Paris).
58:273–277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang HI, Lu SN, Liaw YF, You SL, Sun CA,
Wang LY, Hsiao CK, Chen PJ, Chen DS and Chen CJ; Taiwan
Community-Based Cancer Screening Project Group, : Hepatitis B e
antigen and the risk of hepatocellular carcinoma. N Engl J Med.
347:168–174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lok AS: Prevention of hepatitis B
virus-related hepatocellular carcinoma. Gastroenterology. 127 Suppl
1:S303–S309. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mair RD, Valenzuela A, Ha NB, Ayoub WS,
Daugherty T, Lutchman GA, Garcia G, Ahmed A and Nguyen MH:
Incidence of hepatocellular carcinoma among US patients with
cirrhosis of viral or nonviral etiologies. Clin Gastroenterol
Hepatol. 10:1412–1417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD,
Liu CJ, Chen PJ, Hsiao TJ, Lee PH and Chen CJ: Familial risk of
hepatocellular carcinoma among chronic hepatitis B carriers and
their relatives. J Natl Cancer Inst. 92:1159–1164. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Loomba R, Liu J, Yang HI, Lee MH, Lu SN,
Wang LY, Iloeje UH, You SL, Brenner D and Chen CJ; REVEAL-HBV Study
Group, : Synergistic effects of family history of hepatocellular
carcinoma and hepatitis B virus infection on risk for incident
hepatocellular carcinoma. Clin Gastroenterol Hepatol.
11:1636–1645.e1-3. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Turati F, Edefonti V, Talamini R,
Ferraroni M, Malvezzi M, Bravi F, Franceschi S, Montella M, Polesel
J, Zucchetto A, et al: Family history of liver cancer and
hepatocellular carcinoma. Hepatology. 55:1416–1425. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie KL, Zhang YG, Liu J, Zeng Y and Wu H:
MicroRNAs associated with HBV infection and HBV-related HCC.
Theranostics. 4:1176–1192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Z, Hu Y, Shen X, Lao Y, Zhang L, Qiu
X, Hu J, Gong P, Cui H, Lu S, et al: HBx represses RIZ1 expression
by DNA methyltransferase 1 involvement in decreased miR-152 in
hepatocellular carcinoma. Oncol Rep. 37:2811–2818. 2017.PubMed/NCBI
|
|
11
|
Wu Y, Zhang J, Zhang H and Zhai Y:
Hepatitis B virus X protein mediates yes-associated protein 1
upregulation in hepatocellular carcinoma. Oncol Lett. 12:1971–1974.
2016.PubMed/NCBI
|
|
12
|
Xu C, Zhou W, Wang Y and Qiao L: Hepatitis
B virus-induced hepatocellular carcinoma. Cancer Lett. 345:216–222.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang S and He X: The role of microRNAs in
liver cancer progression. Br J Cancer. 104:235–240. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Braconi C, Huang N and Patel T:
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor
suppressor gene expression by interleukin-6 in human malignant
cholangiocytes. Hepatology. 51:881–890. 2010.PubMed/NCBI
|
|
16
|
Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X
and Wu Z: miR-101 is down-regulated by the hepatitis B virus ×
protein and induces aberrant DNA methylation by targeting DNA
methyltransferase 3A. Cell Signal. 25:439–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei X, Tan C, Tang C, Ren G, Xiang T, Qiu
Z, Liu R and Wu Z: Epigenetic repression of miR-132 expression by
the hepatitis B virus × protein in hepatitis B virus-related
hepatocellular carcinoma. Cell Signal. 25:1037–1043. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dong Y and Wang A: Aberrant DNA
methylation in hepatocellular carcinoma tumor suppression (Review).
Oncol Lett. 8:963–968. 2014.PubMed/NCBI
|
|
19
|
Liu WH, Yeh SH and Chen PJ: Role of
microRNAs in hepatitis B virus replication and pathogenesis.
Biochim Biophys Acta. 1809:678–685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z,
Wang JF, Zhang Z, Lu S, Huang X, et al: Plasma microRNA panel to
diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin
Oncol. 29:4781–4788. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fu Y, Wei X, Tang C, Li J, Liu R, Shen A
and Wu Z: Circulating microRNA-101 as a potential biomarker for
hepatitis B virus-related hepatocellular carcinoma. Oncol Lett.
6:1811–1815. 2013.PubMed/NCBI
|
|
22
|
Katayama Y, Maeda M, Miyaguchi K, Nemoto
S, Yasen M, Tanaka S, Mizushima H, Fukuoka Y, Arii S and Tanaka H:
Identification of pathogenesis-related microRNAs in hepatocellular
carcinoma by expression profiling. Oncol Lett. 4:817–823.
2012.PubMed/NCBI
|
|
23
|
Wang Y, Lu Y, Toh ST, Sung WK, Tan P, Chow
P, Chung AY, Jooi LL and Lee CG: Lethal-7 is down-regulated by the
hepatitis B virus × protein and targets signal transducer and
activator of transcription 3. J Hepatol. 53:57–66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kong G, Zhang J, Zhang S, Shan C, Ye L and
Zhang X: Upregulated microRNA-29a by hepatitis B virus X protein
enhances hepatoma cell migration by targeting PTEN in cell culture
model. PLoS One. 6:e195182011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu G, Yu F, Xiao Z, Xu K, Xu J, Tang W,
Wang J and Song E: Hepatitis B virus X protein downregulates
expression of the miR-16 family in malignant hepatocytes in vitro.
Br J Cancer. 105:146–153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng
X, Zhu Z, Jiao H, Lin J, Jiang K, et al: Hepatitis B virus X
protein represses miRNA-148a to enhance tumorigenesis. J Clin
Invest. 123:630–645. 2013.PubMed/NCBI
|
|
27
|
Liu FY, Zhou SJ, Deng YL, Zhang ZY, Zhang
EL, Wu ZB, Huang ZY and Chen XP: MiR-216b is involved in
pathogenesis and progression of hepatocellular carcinoma through
HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis.
6:e16702015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hassan MM, Spitz MR, Thomas MB, Curley SA,
Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, et
al: The association of family history of liver cancer with
hepatocellular carcinoma: A case-control study in the United
States. J Hepatol. 50:334–341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang ZZ, Liu X, Wang DQ, Teng MK, Niu LW,
Huang AL and Liang Z: Hepatitis B virus and hepatocellular
carcinoma at the miRNA level. World J Gastroenterol. 17:3353–3358.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X,
Zhou X and Gan J: A serum microRNA panel as potential biomarkers
for hepatocellular carcinoma related with hepatitis B virus. PLoS
One. 9:e1079862014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan
J, Wu J and Li M: MicroRNA-374a activates Wnt/β-catenin signaling
to promote breast cancer metastasis. J Clin Invest. 123:566–579.
2013.PubMed/NCBI
|
|
32
|
Della Vittoria, Scarpati G, Falcetta F,
Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK,
D'Incalci M, De Placido S and Pepe S: A specific miRNA signature
correlates with complete pathological response to neoadjuvant
chemoradiotherapy in locally advanced rectal cancer. Int J Radiat
Oncol Biol Phys. 83:1113–1119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo
J, Wang Y and Xu Y: miR-188-5p inhibits tumour growth and
metastasis in prostate cancer by repressing LAPTM4B expression.
Oncotarget. 6:6092–6104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao
Y, Tang J, Chen X, Dai J, Wei Q, et al: Serum microRNA profiling
and breast cancer risk: The use of miR-484/191 as endogenous
controls. Carcinogenesis. 33:828–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Macconi D, Tomasoni S, Romagnani P,
Trionfini P, Sangalli F, Mazzinghi B, Rizzo P, Lazzeri E, Abbate M,
Remuzzi G and Benigni A: MicroRNA-324-3p promotes renal fibrosis
and is a target of ACE inhibition. J Am Soc Nephrol. 23:1496–1505.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dharap A, Pokrzywa C, Murali S, Pandi G
and Vemuganti R: MicroRNA miR-324-3p induces promoter-mediated
expression of RelA gene. PLoS One. 8:e794672013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB,
Robinson BG and Soon PSh: MicroRNA-484 is more highly expressed in
serum of early breast cancer patients compared to healthy
volunteers. BMC Cancer. 14:2002014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang K, Long B, Jiao JQ, Wang JX, Liu JP,
Li Q and Li PF: miR-484 regulates mitochondrial network through
targeting Fis1. Nat Commun. 3:7812012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ,
Wang TY, Li HC and Wu XN: Differential expression of miRNAs in
esophageal cancer tissue. Oncol Lett. 5:1639–1642. 2013.PubMed/NCBI
|
|
40
|
Niu G, Li B, Sun J and Sun L: miR-454 is
down-regulated in osteosarcomas and suppresses cell proliferation
and invasion by directly targeting c-Met. Cell Prolif. 48:348–355.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu L, Nie J, Chen L, Dong G, Du X, Wu X,
Tang Y and Han W: The oncogenic role of microRNA-130a/301a/454 in
human colorectal cancer via targeting Smad4 expression. PLoS One.
8:e555322013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu L, Gong X, Sun L, Yao H, Lu B and Zhu
L: miR-454 functions as an oncogene by inhibiting CHD5 in
hepatocellular carcinoma. Oncotarget. 6:39225–39234.
2015.PubMed/NCBI
|
|
43
|
Zhao M, Luo R, Liu Y, Gao L, Fu Z, Fu Q,
Luo X, Chen Y, Deng X, Liang Z, et al: miR-3188 regulates
nasopharyngeal carcinoma proliferation and chemosensitivity through
a FOXO1-modulated positive feedback loop with
mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 7:113092016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Deng M, Tang H, Zhou Y, Zhou M, Xiong W,
Zheng Y, Ye Q, Zeng X, Liao Q, Guo X, et al: miR-216b suppresses
tumor growth and invasion by targeting KRAS in nasopharyngeal
carcinoma. J Cell Sci. 124:2997–3005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ye H, Zhang C, Wang BJ, Tan XH, Zhang WP,
Teng Y and Yang X: Synergistic function of Kras mutation and HBx in
initiation and progression of hepatocellular carcinoma in mice.
Oncogene. 33:5133–5138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim SY, Lee YH and Bae YS: MiR-186,
miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular
senescence by targeting α subunit of protein kinase CKII in human
colorectal cancer cells. Biochem Biophys Res Commun. 429:173–179.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ali S, Banerjee S, Logna F, Bao B, Philip
PA, Korc M and Sarkar FH: Inactivation of Ink4a/Arf leads to
deregulated expression of miRNAs in K-Ras transgenic mouse model of
pancreatic cancer. J Cell Physiol. 227:3373–3380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Anson M, Crain-Denoyelle AM, Baud V,
Chereau F, Gougelet A, Terris B, Yamagoe S, Colnot S, Viguier M,
Perret C and Couty JP: Oncogenic β-catenin triggers an inflammatory
response that determines the aggressiveness of hepatocellular
carcinoma in mice. J Clin Invest. 122:586–599. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cha MY, Kim CM, Park YM and Ryu WS:
Hepatitis B virus X protein is essential for the activation of
Wnt/beta-catenin signaling in hepatoma cells. Hepatology.
39:1683–1693. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fang F, Chang RM, Yu L, Lei X, Xiao S,
Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell
proliferation and metastasis by directly targeting FGF5 in
hepatocellular carcinoma. J Hepatol. 63:874–885. 2015. View Article : Google Scholar : PubMed/NCBI
|
